Cost‐effectiveness of office‐based, magnetic resonance imaging‐guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial
Cancer · 2025
DOI: 10.1002/cncr.70118 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2025. Verfasst von Mitchell M Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Image-Guided Biopsy, Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
As antimicrobial resistance increases, safer alternative approaches to prostate biopsy are needed. PREVENT was a multi‐institutional, randomized controlled trial comparing transperineal (TP) biopsy without antibiotic prophylaxis versus transrectal (TR) biopsy with targeted prophylaxis. The authors conducted a secondary cost‐effectiveness analysis of PREVENT.
Methods
The authors designed a Markov model with a simulated cohort of 1000 biopsied men. They assessed the short‐term cost‐effectiveness over a 2‐week period, comparing relative costs in US dollars and utility measured in quality‐adjusted life years (QALYs). The strategies they compared were office‐based, magnetic resonance imaging‐guided biopsy using two approaches: (1) TP without antibiotics; or (2) TR with targeted antibiotic prophylaxis. Analysis was from a health care payer perspective using a willingness‐to‐pay (WTP) threshold of $100,000/QALY. Probabilistic sensitivity analysis was performed with 5000 Monte Carlo simulations.
Results
Compared to TR, TP was dominant, offering lower cost and higher utility per patient. This finding was robust to sensitivity analyses with TP having >89% probability of cost‐effectiveness regardless of WTP threshold. TP remained dominant when real‐world infection rates were used. TP biopsy needed to prevent >0.5% infections compared to TR to maintain cost‐effectiveness. Per 1000 patients, TP biopsy prevented 16 infections, and the additional cost to prevent a single infection was $3.18/patient.
Conclusions
In this model, TP biopsy was more cost‐effective than TR from a health care payer perspective. In the setting of increasing concerns about the risk of infection from traditional TR biopsy, these findings suggest that office‐based TP biopsy is a more cost‐effective population‐level alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Urology, Weill Cornell Medicine, New York, New York, USA.
- Department of Surgery and Perioperative Care, The University of Texas at Austin Dell Medical School, Austin, Texas, USA.
- Surgery Service, Jesse Brown VA Medical Center, Chicago, Illinois, USA.
- Department of Population Health Sciences, Weill Cornell Medical College, New York, New York, USA.
ORCID-Profile: Conor B Driscoll, Hiten D Patel
Förderung
- NCI NIH HHS
Zitieren
APA
Huang, M. M., Driscoll, C. B., Handa, N., Wahba, B. M., Laviana, A. A., Patel, H. D., Jalali, A., Hu, J. C., & Schaeffer, E. M. (2025). Cost‐effectiveness of office‐based, magnetic resonance imaging‐guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial. Cancer. https://doi.org/10.1002/cncr.70118
Vancouver
Huang MM, Driscoll CB, Handa N, Wahba BM, Laviana AA, Patel HD, et al. Cost‐effectiveness of office‐based, magnetic resonance imaging‐guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial. Cancer. 2025. doi:10.1002/cncr.70118
BibTeX
@article{Huang2025,
author = {Huang, Mitchell M and Driscoll, Conor B and Handa, Nicole and Wahba, B Malik and Laviana, Aaron A and Patel, Hiten D and Jalali, Ali and Hu, Jim C and Schaeffer, Edward M},
title = {Cost‐effectiveness of office‐based, magnetic resonance imaging‐guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70118}
}
EUVIMED